Celgene

Principal Scientist, Medicinal Chemistry

Posted on: 6 Jul 2021

Redwood City, CA

Job Description

Job Title/Description

We are seeking an exceptionally talented and highly motivated medicinal chemist who is passionate about joining our fast-paced medicinal chemistry group in the pursuit of discovering innovative therapies in Oncology. A strong proficiency in fundamental aspects of drug discovery and demonstrated ability to lead or co-lead multi-disciplinary discovery programs and advancing them to critical milestones is required. She/he will contribute to programs by setting strategies, priorities, and driving critical path drug discovery objectives. The candidate should have relevant supervisory experience with internal direct reports as well as external CROs. Candidates must have experience in the independent design and execution of multistep syntheses of complex organic molecules using modern organic chemistry.  Excellent hypothesis driven problem-solving skills and a thorough understanding of medicinal chemistry principles, synthetic methods, and reaction mechanisms are required. Candidates will have expertise in the purification and characterization of organic compounds. Excellent oral and written communication skills and a desire to work in a collaborative team environment are required. A track record of innovation documented through co-inventorship on issued patents and authorship of publications in peer-reviewed journals is necessary.  Knowledge in E3 ligase and UPS biology is a plus as protein homeostasis is one of the fundamental research engines at BMS delivering therapeutics to patients. Not being bound by therapeutic modality creates a very dynamic, exciting and creative environment where the successful chemist will interface with an excellent team of scientists in biology, biochemistry, structural biology, computational biology and translational development.

Qualifications

Ph.D. with 7+ years of medicinal chemistry experience in a pharma or biotech environment
M.S. degree with 10+ years or a B.S. degree with 12+ years of industrial medicinal chemistry experience.
Track record of innovation and impact on programs documented through co-inventorship on issued patents and authorship of publications in peer-reviewed journals (may include both successful advances and smart terminations).
High level of creativity and productivity with strong synthetic problem-solving skills, synthetic methods, and reaction mechanisms are required.
Committed to experimental work – skilled in multi-step synthesis, purification, and state-of-the-art techniques for characterization of organic compounds.
Strong skills in gathering, documenting, and analyzing information from competitive sources such as patents or conferences and using this information to guide program strategy.

Experience with supervising Ph.D. and associate level scientists to high levels of productivity, whilst improving the skills and knowledge of direct reports through mentorship.
Broad knowledge of the drug discovery and development process.
A naturally collaborative style as necessary to work effectively in a fast-paced, highly integrated team environment.
Excellent written and oral communication skills demonstrated ability to write peer reviewed quality work or invention disclosures for patent applications, and able to present the rationale, key data, issues and accomplishments department wide.

Preferred Qualifications

Experience working in the field of protein degradation and understanding of E3 ligase biology

Travel Required

Local and international travel for conferences and regulatory meetings may be required depending on project needs up to 5-10% of the time

Fit with BMS Culture and Values

Diversity, inclusion and integrity
Strong team orientation; highly collaborative
Solutions and results-oriented focus
Hands-on approach; resourceful and open to diverse points of view

Celgene

Summit, NJ

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

The company’s products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology.

The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; EXSCIENTIA LTD.; and IMIDomics SL, as well as immuno-oncology collaboration with Sutro Biopharma. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.